Systemic and lung physiological changes in rats after intravascular activation of complement

Journal of Applied Physiology

Volumn 90, Issue 6, 2001, Pages 2289-2295

  Younger, John G ^a   Sasaki, Nobuyoshi ^c   Delgado, Joao ^a   Ko, Angela C ^a   Nghiem, Trac X ^a   Waite, Michael D ^b   Till, Gerd O ^a   Ward, Peter A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

C5a; Cobra venom factor; Cyclooxygenase 1 and 2; Neutrophils; Shock

Indexed keywords

ALBUMIN; COBROTOXIN; COMPLEMENT COMPONENT C5A; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL PERMEABILITY; COMPLEMENT ACTIVATION; HYPOTENSION; HYPOXEMIA; LUNG FUNCTION; LUNG INJURY; MALE; METABOLIC ACIDOSIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; SHOCK;

EID: 0035018441     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/jappl.2001.90.6.2289     Document Type: Article

References (25)

1. Ballow M and Cochrane C. Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them. J Immunol 103: 944-952, 1969.
2. Bhattacharya J. Physiological basis of pulmonary edema. In: Pulmonary Edema, edited by Matthay M and Ingbar D. New York: Dekker, 1998, p. 1-36.
3. Bodammer G and Vogt W. Actions of anaphylatoxin on circulation and respiration in the guinea pig. Int Arch Allergy 32: 417-428, 1967.
4. Fitch J, Rollins S, Matis L, Alford B, Aranki S, Collard C, Dewar M, Elefteriades J, Hines R, Kopf G, Kraker P, Li L, O'Hara R, Rinder C, Rinder H, Shaw R, Smith B, Stahl G, and Shernan S. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 100: 2499-2506, 1999.
5. Fosse E, Mollnes T, Aasen A, Trumpy J, and Stokke T. Complement activation following multiple injuries. Acta Chir Scand 153: 325-330, 1987.
6. Hecke F, Schmidt U, Kola A, Bautsch W, Klos A, and Kohl J. Circulating complement proteins in multiple trauma patients: correlation with injury severity, development of sepsis, and outcome. Crit Care Med 25: 2015-2024, 1997.
7. Heideman M, Kaijser B, and Gelin L. Complement activation and hematologic, hemodynamic, and respiratory reactions early after soft-tissue injury. J Trauma 18: 696-700, 1978.
8. Heideman M, Norder-Hansson B, Bengston A, and Mollnes T. Terminal complement complexes and anaphylatoxins in septic and ischemic patients. Arch Surg 123: 188-192, 1988.
9. Heideman M, Saravis C, and Clowes G. Effect of nonviable tissue and abscesses on complement depletion and the development of bacteremia. J Trauma 22: 527-532, 1982.
10. Hicks R and Sackeyfio A. The nature of adrenergic mechanisms involved in anaphylatoxin activity in the guinea-pig. Br J Pharmacol 46: 260-269, 1972.
11. Huey R, Bloor C, Kawahara M, and Hugli T. Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase (SCPN). I. Lethality and pathologic effects on pulmonary tissue. Am J Pathol 112: 48-60, 1983.
12. Ikai M, Itoh M, Joh T, Yokoyama Y, and Okada N. Complement plays an essential role in shock following intestinal ischemia in rats. Clin Exp Immunol 106: 156-159, 1996.
13. Kochilas L, Campbell B, Scalia R, and Lefer A. Beneficial effects of C1 esterase inhibitor in murine traumatic shock. Shock 8: 165-169, 1997.
14. Langlois P and Gawryl M. Accentuated formation of the terminal C5b-9 complement complex in patient plasma precedes development of the adult respiratory distress syndrome. Am Rev Respir Dis 138: 368-375, 1988.
15. Mohr M, Hopken U, Oppermann M, Mathes C, Goldmann K, Siever S, Gotze O, and Burchardi H. Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis. Eur J Clin Invest 28: 227-234, 1998.
16. Pavek K, Piper P, and Smedegard G. Anaphylatoxin-induced shock and two patterns of anaphylactic shock: hemodynamics and mediators. Acta Physiol Scand 105: 393-403, 1979.
17. Plummer T and Ryan T. A potent mercapto by-product analogue inhibitor for human carboxypeptidase-N. Biochem Biophys Res Commun 98: 448-454, 1981.
18. Schirmer W, Schirmer J, Naff G, and Fry D. Complement-mediated hemodynamic depression in the early postburn period. J Trauma 29: 932-938, 1989.
19. Spain D, Fruchterman T, Matheson P, Wilson M, Martin A, and Garrison R. Complement activation mediates intestinal injury after resuscitation from hemorrhagic shock. J Trauma 46: 224-233, 1999.
20. Tegeder I, Neupert W, Guhring H, and Geisslinger G. Effects of selective and unselective cyclooxygenase inhibitors on prostanoid release from various rat organs. J Pharmacol Exp Ther 292: 1161-1168, 2000.
21. Till G, Johnson K, Kunkel R, and Ward P. Intravascular activation of complement and acute lung injury. J Clin Invest 69: 1126-1135, 1981.
22. Weigelt J, Chenoweth D, Borman K, and Norcross J. Complement and the severity of pulmonary failure. J Trauma 28: 1013-1019, 1988.
23. Williams J, Pechet T, Weiser M, Reid R, Kobzik L, Moore JFD, Carroll M, and Hechtman H. Intestinal reperfusion injury is mediated by IgM and complement. J Appl Physiol 86: 938-942, 1999.
24. Younger J, Sasaki N, Waite M, Murray H, Saleh E, Ravage Z, Hirschl R, Ward P, and Till G. Detrimental effects of complement activation in hemorrhagic shock. J Appl Physiol 90: 441-446, 2001.
25. Zilow G, Sturm J, Rother U, and Kirschfink M. Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome. Clin Exp Immunol 79: 151-157, 1990.